Even though HCQ+zinc+AZ is 99+% effective in early OUTpatient treatment, and according to results at Henry Ford and Mt. Sinai Hospitals even still 50% effective in the early INpatient setting (without even all 3 elements of the $14 protocol being used), the NIH predictably continues to discourage its use in favor of $3,200 Remdesivir, about which the NIH's own study suggested did not result in a "statistically significant difference in mortality".
https://www.covid19treatmentguidelines.nih.gov/whats-new/"September 1, 2020
The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Convalescent Plasma for the Treatment of COVID-19
The Food and Drug Administration issued an Emergency Use Authorization for COVID-19 convalescent plasma for the treatment of hospitalized patients with COVID-19. Based on the available evidence, the Panel has determined the following:
There are insufficient data to recommend either for or against the use of convalescent plasma for the treatment of COVID-19.
Convalescent plasma should not be considered the standard of care for the treatment of patients with COVID-19.
Prospective, well-controlled, adequately powered randomized trials are needed to determine whether convalescent plasma is effective and safe for the treatment of COVID-19. Members of the public and health care providers are encouraged to participate in these prospective clinical trials."
Yet convalescent plasma therapy has been highly effective in treatment of COVID-19 and has been used for over 100 years.https://www.covid-19forum.org/index.php?topic=247.msg323#msg323August 27, 2020
Key Updates to the Guidelines
Chloroquine or Hydroxychloroquine With or Without Azithromycin
To reflect the results of large randomized controlled trials that enrolled hospitalized patients, the following recommendations have been updated to differentiate between hospitalized and nonhospitalized patients:
The Panel recommends against the use of chloroquine or hydroxychloroquine for the treatment of COVID-19 in hospitalized patients (AI).
In nonhospitalized patients, the Panel recommends against the use of chloroquine or hydroxychloroquine for the treatment of COVID-19, except in a clinical trial (AI)."
And so the FDA, NIH led slaughter of the American people on the alter of Big Pharma continues, as they denigrate highly effective treatments, even as they
lower the requirements for patients to receive $3,200 Remdesivir
to children with just suspected COVID at any stage of disease development, about which the NIH's own study revealed the "difference in mortality was not statistically significant", and known side effects are damage to liver and kidneys and according to Dr. Zev Zelenko with 6% having heart issues.
https://www.covid-19forum.org/index.php?topic=19.msg388#msg388
